Phase 2 Single Arm, Two Cohort Study Evaluating AMG 337 in Subjects with MET Amplif. GI/GEJ/E cancer

Diseases and Conditions Researched

Esophagus; Stomach

What is the purpose of this trial?

Determine antitumor activity of AMG 337 in subjects with MET amplified gastric, (G)
gastroesophageal junction (GEJ), or esophageal (E) adenocarcinoma (Cohort 1).

Participation Guidelines

Age: 18 Years and older
Gender: Both

Click here for detailed participation information for this trial.

Sponsor: Amgen, Inc.
Last Updated:
Study HIC#: 1402013465